Early lenalidomide treatment for low and intermediate‐1 International Prognostic Scoring System risk myelodysplastic syndromes with del(5q) before transfusion dependence

Lenalidomide is approved for the treatment of transfusion‐dependent (TD) del(5q) myelodysplastic syndromes (MDS). However, few data are available in patients with transfusion‐independent (TI) del(5q) MDS. In the first, observational, part of this 2‐part study, we assessed the impact of transfusion d...

Descripción completa

Detalles Bibliográficos
Autores principales: Oliva, Esther N., Lauseker, Michael, Aloe Spiriti, Maria Antonietta, Poloni, Antonella, Cortelezzi, Agostino, Palumbo, Giuseppe A., Balleari, Enrico, Sanpaolo, Grazia, Volpe, Antonio, Ricco, Alessandra, Ronco, Francesca, Alati, Caterina, D'Errigo, Maria Grazia, Santacaterina, Irene, Kündgen, Andrea, Germing, Ulrich, Latagliata, Roberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2015
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5123712/
https://www.ncbi.nlm.nih.gov/pubmed/26376955
http://dx.doi.org/10.1002/cam4.523

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5123712/
https://www.ncbi.nlm.nih.gov/pubmed/26376955
http://dx.doi.org/10.1002/cam4.523

Ejemplares similares